Return to content in this issue

 

Tezepelumab in Patients With Severe Asthma: Response at 3 Months

Miralles-López JC1, Andújar-Espinosa R2, Bravo-Gutierrez FJ3, Cabrejos-Perotti S4, Ramírez-Hernández Mercedes4, Díaz-Chantar C5, Pajarón Fernández MJ6, Valverde-Molina J7, Pérez-Fernández V8, RE-ASGRAMUR GROUP*

1Allergy Department, University General Hospital Reina Sofía, Murcia, Spain
2Pulmonology Department, University Clinic Hospital Virgen de la Arrixaca, Murcia, Spain
3Pulmonology Department, University General Hospital Santa Lucia, Cartagena, Murcia, Spain
4Allergy Department, University General Hospital Santa Lucia, Cartagena, Murcia, Spain
5Pulmonology Department, Hospital de la Vega Lorenzo Guirao, Cieza, Spain
6Allergy Department, Hospital de la Vega Lorenzo Guirao, Cieza, Spain
7Pediatrics Department, University General Hospital Santa Lucia, Cartagena, Murcia, Spain
8Department of Public Health Sciences, University of Murcia, School of Medicine, Murcia, Spain
*Members of the RE-ASGRAMUR (Register of Severe Asthma of the Region of Murcia) Group are listed in Supplementary Appendix 1.

J Investig Allergol Clin Immunol 2025; Vol. 35(2)
doi: 10.18176/jiaci.1041

Key words: Severe asthma, Tezepelumab, Real-life, Response to treatment